Genmab CEO says lower operating costs are a fleeting phenomenon
Genmab has revised its 2021 forecast for operating expenses, which includes research and development costs. Though whatever has been saved goes straight to next year, says the company's president and CEO, who points to Covid-19 as the cause for spending delays.
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN
Before Wedneday's quarterly report from Genmab was released, the biotech company had already upgraded its 2021 financial guidance for revenue and operating result.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
